Synthetic opioids: can Europe keep up with a new drug created every week?
Poinews.com – Europe’s drug landscape is evolving at an alarming rate, with a fresh psychoactive substance entering the market roughly every seven days. According to the European Union Drugs Agency (EUDA), synthetic opioids present a dire threat, as a single gram of these compounds could contain thousands of potentially fatal doses. This assessment is part of the EUDA’s 2026 European Drug Report, released on 9 June, which reveals that 50 novel drugs were identified in Europe alone during 2025. Among these, synthetic opioids and cathinones dominate, highlighting a growing trend in the region’s illicit drug scene.
The EUDA now oversees over 1,000 new psychoactive substances through its Early Warning System, a number that has surged from negligible levels just a decade ago. Notably, “orphine” opioids—semi-synthetic compounds—have emerged as a critical concern since 2024. Nine of these substances have been linked to more than 30 deaths across the continent. Two, cychlorphine and spirochlorphine, have already spread to over a dozen countries and are being prioritized for EU-level risk evaluation.
“It’s hard to distil it down to one factor, because the market responds to multiple issues,” said Lorraine Nolan, EUDA’s Executive Director. She pointed to organised crime, migration pressures, and geopolitical shifts as key forces reshaping drug supply in Europe.
Nolan emphasized that Europe has become a key production hub for synthetic opioids, with hundreds of clandestine laboratories operating annually. This follows the continent’s established history of amphetamine manufacturing and the adoption of more advanced equipment. “The situation is challenging because of the pace of advancement and the very fast emergence of new substances,” she added, noting that each new compound brings health risks yet to be fully understood.
Despite the rapid influx of new drugs, the EU is maintaining its footing. In July 2024, the EUDA expanded its mandate to introduce tools that accelerate response times: a Drug Alert System for immediate frontline warnings, a threat-assessment unit to predict substance behavior, and a network of forensic labs for faster analysis. These measures aim to streamline the process from detection to regulation, with several synthetic opioids currently under active risk evaluation for potential EU-wide control.
The report underscores Europe’s relative success compared to other regions. In 2024, the EU recorded approximately 7,600 drug-related deaths, far fewer than the over 100,000 reported annually in the United States. Nolan attributed this to the bloc’s “balanced approach,” which integrates enforcement with investment in treatment and harm reduction initiatives. Over 60% of Europe’s 800,000 problem opioid users—more than 500,000 individuals—now receive opioid agonist therapy, while take-home naloxone is accessible in 19 member states.
A New Strategy for Europe
The EU’s 2026-2030 Drugs Strategy, approved in June, marks a significant shift toward a comprehensive framework. It focuses on five pillars: public health, security, harm reduction, partnerships, and preparedness. The strategy seeks to address past policies that treated supply and demand as separate issues, instead prioritizing the interplay between these factors. Under the new plan, the EUDA’s role is advisory, providing data, training, and monitoring to support national efforts rather than enforcing decisions directly.
Nolan highlighted that cooperation with Europol and Frontex is strengthening, as trafficking networks grow more complex and intertwined with organised violence. The agency currently holds the presidency of the EU’s Justice and Home Affairs agencies network, with its current agenda emphasizing the connection between health, security, and emerging technological threats. Brussels is wagering on these reforms to ensure Europe remains ahead of the ever-changing drug landscape.
